Summary
Eli Lilly & Company (LLY) filed an amendment to its Form 10-Q for the period ending March 31, 2008, primarily to restate its consolidated condensed balance sheets as of March 31, 2008, and December 31, 2007. This restatement was necessitated by an adjustment to the company's reserve for future product returns, which was found to be understated by $247.5 million. The company has clarified that this restatement has no impact on its income, cash flows, or overall liquidity, and the effects on its financial position were deemed immaterial to any single prior period. Operationally, the first quarter of 2008 showed robust sales growth of 14% year-over-year, reaching $4.81 billion, driven by key products like Cymbalta, Cialis, Humalog, Alimta, and Gemzar. Net income significantly increased to $1.06 billion, or $0.97 per diluted share, compared to $508.7 million, or $0.47 per diluted share, in the prior year's first quarter. This strong performance was bolstered by a discrete income tax benefit of $210.3 million from the resolution of a significant portion of the IRS audit for tax years 2001-2004. However, the company also incurred charges related to the termination of the AIR Insulin program and in-process research and development for a new licensing arrangement, which impacted earnings.
Key Highlights
- 1Worldwide sales increased by 14% to $4.81 billion in the first quarter of 2008 compared to the same period in 2007, driven by growth in key products.
- 2Net income more than doubled to $1.06 billion ($0.97 per diluted share) in Q1 2008 from $508.7 million ($0.47 per diluted share) in Q1 2007.
- 3The company recognized a significant $210.3 million discrete income tax benefit due to the resolution of a portion of its IRS income tax audit (2001-2004).
- 4A restatement of the balance sheets as of March 31, 2008, and December 31, 2007, was filed due to an understatement in the reserve for future product returns by $247.5 million, with no material impact on income, cash flow, or liquidity.
- 5Significant charges were recorded in Q1 2008 related to the termination of the AIR Insulin program ($145.7 million) and in-process R&D for a new licensing arrangement ($87.0 million).
- 6The company's top-selling product, Zyprexa, saw a 5% decrease in U.S. sales but a 6% increase in international sales.
- 7Total debt decreased by $285.9 million from December 31, 2007, to $4.72 billion as of March 31, 2008.